Pediatric Gastrointestinal Neoplasms: Background, Esophageal Neoplasms, Gastric Neoplasms (original) (raw)

Background

Primary gastrointestinal (GI) neoplasms in children are rare. [1] In 1960, the incidence of GI malignancies arising from the bowel was estimated at less than 1% of pediatric tumors, and most of the diagnoses were made during urgent exploration for an abdominal crisis. This is in contrast to adults, in whom 22% of malignancies are located in the GI tract; furthermore, most adults have long-standing symptoms (eg, pain, weight loss, and bleeding). Like other pediatric cancers, those of the GI tract differ from corresponding cancers in adults in terms of histology, pathogenesis, and clinical presentation. [2]

Much of the pediatric literature regarding GI malignancies consists of case reports. Consequently, this article focuses on the more common benign and malignant neoplasms of the GI tract in children, in addition to information gleaned from the relatively sparse literature.

eMedicine Logo

Esophageal Neoplasms

Benign and malignant smooth-muscle tumors of the esophagus in children account for fewer than 5% of all leiomyomas and leiomyosarcomas. Tumors in the pediatric population, in contrast to those in adults, are multiple; localized tumors represent only 9% of cases. In children, these tumors are more commonly found in girls than in boys.

Presenting symptoms include dysphagia, retained food, and chest pain. Barium swallow reveals proximal dilation that is easily confused with achalasia. Esophagoscopy reveals a mucosa-covered narrowing; biopsy is diagnostic. The treatment for symptomatic lesions is surgical resection, which often requires esophageal replacement because of the diffuse nature of the disease. [3] One series reported that only 11% of leiomyomas were amenable to enucleation. [4]

Children with long-standing gastroesophageal reflux disease (GERD) are at risk for developing Barrett esophagus, dysplasia, and adenocarcinoma in a progression similar to that seen in adults. [5, 6, 7, 8] In one reflux series, 13% of children who underwent surveillance endoscopy and biopsy were found to have Barrett esophagus. Children born with esophageal atresia may be at increased risk for the development of Barrett esophagus. [9]

In view of the small number of pediatric cases of Barrett esophagus reported in the literature, surveillance and treatment are based on adult recommendations. Every patient needs aggressive medical treatment. Cases that have advanced to metaplasia should be seriously considered for antireflux procedures. High-grade dysplasia or adenocarcinoma of the esophagus requires esophagectomy and gastric pull-up or bowel interposition for reconstruction.

eMedicine Logo

Gastric Neoplasms

Gastric teratomas comprise fewer than 1% of all childhood teratomas. Clinical presentation generally occurs within the first 3 months of life as an abdominal mass, abdominal distention, emesis, GI bleeding, anemia, and respiratory distress. Teratomas in this location occur predominantly in males (96%); no cases of malignant transformation have been reported.

Diagnosis is made with ultrasonography (US), computed tomography (CT), or both; these modalities reveal the characteristic heterogenous appearance, including fat, calcifications, and cystic areas. Most cases are treated with simple resection (see the images below), but partial gastrectomy may be necessary.

An intraoperative view of a gastric teratoma being

An intraoperative view of a gastric teratoma being resected.

The gross specimen of a gastric teratoma after res

The gross specimen of a gastric teratoma after resection. Note the heterogeneity of the tumor.

Gastric cancer is rare in the pediatric population. [10] Gastric carcinoma accounts for only 0.05% of GI malignancies in childhood. Symptoms are often similar to those of peptic ulcer disease and include pain and vomiting. The diagnosis is made by upper endoscopy with biopsy or upper GI contrast series.

Because of the rarity of this lesion, recommendations for therapy are based on the adult literature. The first step is to determine if the child is an operative candidate. CT and intraesophageal US both are useful in determining the extent of disease. Complete or partial gastrectomy may be performed with resection of surrounding lymph nodes; however, the overall prognosis is poor. Surgical resection with or without concomitant chemotherapy and radiation may prolong survival, but mortality remains high.

eMedicine Logo

Gastrointestinal Lymphoma

Lymphoma is the most common small-bowel malignancy in the pediatric age group. In one of the larger series, non-Hodgkin lymphomas (NHLs) accounted for 74% of alimentary tract malignancies. [11, 12] (See the image below.) Tumors were found in the colon (50.9%), small bowel (21.8%), and stomach (1.8%). Many other series identify 50-93% of patients who have primary intestinal lymphomas located in the ileocecal region.

A non-Hodgkin lymphoma present in the mid jejunum

A non-Hodgkin lymphoma present in the mid jejunum at the time of resection.

The most common histologic subtype of these tumors is Burkitt lymphoma, which accounts for as many as 75% of the lesions. Correct preoperative diagnosis rarely occurs, and laparotomy with tissue evaluation is used for diagnosis.

Patients generally have a history of nonspecific chronic abdominal pain and present urgently with an acute exacerbation caused by intussusception (46%), appendicitis (22%), perforation (11%), or bowel obstruction (8%). Physical examination may reveal occult blood per rectum, a palpable abdominal mass, or both. CT and MRI may be useful in cases where clinical suspicion is high. [13] If the diagnosis is made preoperatively, a bone marrow biopsy is performed to rule out metastatic disease. Otherwise, this study is required after laparotomy as part of the staging of the lymphomatous disease.

Surgical management of GI NHL depends on the stage of disease at presentation. Tumor burden is the most reliable prognostic factor. Bulky disease can rarely be completely resected, and aggressive debulking has not shown a survival benefit. In these cases, surgery should be limited to evaluating the extent of disease and obtaining adequate tissue for diagnosis, followed by intensive multiagent chemotherapy. Perforation has been described as a potential complication of rapid regression of the tumor from the bowel wall secondary to chemotherapy. [14]

In cases of localized disease, complete surgical resection includes removal of the primary tumor and thorough examination of mesenteric lymph nodes, liver, and para-aortic lymph nodes to assess for metastatic disease. Complete surgical resection is followed by a histopathologically specific chemotherapy protocol, but the duration and intensity of therapy are decreased because the stage is lower.

eMedicine Logo

Carcinoid Tumors

Carcinoid tumors are derived from enterochromaffin cells located throughout the GI tract. Overall, carcinoids are most commonly found in the ileum (30%), the appendix (30%), and, less frequently, the remaining intestine. Enterochromaffin cells are not usually present in the GI tract until after age 4 years; thus, most carcinoids in children occur after age 5 years. The yearly incidence of carcinoid tumors occurring in children aged 10-15 years is 0.4-0.8 per 100,000 population.

Most children present with symptoms of acute appendicitis, which are likely caused by luminal obstruction by the tumor. [15] Rarely, carcinoids first manifest with carcinoid syndrome, an indication of metastasis to the liver or beyond. This consists of flushing, tachycardia, diarrhea, and asthma secondary to release of serotonin, substance P, or other vasoactive mediators that do not pass through hepatic deactivation before entering the systemic circulation.

In these cases, diagnosis is confirmed by finding elevated urinary levels of 5-hyroxyindoleacetic acid (5-HIAA), which is a metabolite of serotonin. If 5-HIAA is elevated, further localization of the tumor is possible through the use of CT or magnetic resonance imaging (MRI).

Appendiceal carcinoids are almost never metastatic, but 70% of ileal and cecal carcinoids metastasize. The distinction between benign and malignant tumors is the presence of metastasis rather than histologic features.

Appendiceal carcinoids smaller than 2 cm are treated with a simple appendectomy. [15] Tumors larger than 2 cm have a higher frequency of metastasis and are treated with a right hemicolectomy. Treatment of small-bowel carcinoids requires wide resection and regional lymph node sampling. At the time of surgery, an intense yellow appearance aids in the diagnosis, and care is taken during surgery because carcinoid crisis can occur from sudden release of vasoactive mediators.

Overall survival in children is excellent, especially for the common smaller (< 2 cm) carcinoids of the appendix.

eMedicine Logo

Polypoid Disease of the Gastrointestinal Tract

Juvenile polyps (see the image below) are the most common type of neoplasm in the GI tract, accounting for 80% of polyps in children. Grossly, the polyps appear beefy red and range in diameter from several millimeters to several centimeters. Histologically, these lesions represent benign hamartomas and have no malignant potential.

Operative view of a pedunculated juvenile polyp fo

Operative view of a pedunculated juvenile polyp found in the mid jejunum.

Juvenile polyps commonly manifest as painless rectal bleeding in toddlers but may manifest with prolapse (4%) or abdominal pain (10%). [16] Diagnosis is made through a thorough history, rectal examination, sigmoidoscopy, colonoscopy, and/or a contrast enema (generally an air/contrast enema; see the image below).

The barium enema of the patient with familial poly

The barium enema of the patient with familial polyposis. Note the multiple filling defects throughout the colon.

Polyps in the distal colon and rectum are easily resected via endoscopic polypectomy. [17] More proximal lesions are resected endoscopically, rarely with colotomy and polypectomy, or are left to slough spontaneously if adequate visualization of the entire colon demonstrates fewer than five polyps, thus excluding the diagnosis of juvenile polyposis syndromes. If five or more polyps are identified, complete excision of all polyps is preferred, either via colonoscopy or surgical excision with multiple enterotomies for less accessible lesions. This eliminates the problem and yields tissue to correctly characterize the polyp type.

Juvenile polyposis syndrome is a dominantly inherited disorder that can occur as diffuse juvenile polyposis of infancy (0-3 months), diffuse juvenile polyposis (6 months to 5 years), and juvenile polyposis coli (5-15 years). Presenting signs include diarrhea, rectal bleeding, intussusception, anemia, prolapse, and failure to thrive. The diagnosis is made by using the same diagnostic modalities discussed above, and the presence of five or more polyps in sporadic cases or one polyp in cases with a family history confirms the diagnosis.

These children are at high risk for malignancy (17%) occurring by the fourth decade of life and need long-term surveillance. Many surgeons recommend prophylactic colectomy and rectal mucosectomy with endorectal pull-through as the primary treatment for this disease as soon as the diagnosis is established.

Peutz-Jeghers syndrome, another autosomal dominant disease, is characterized by the presence of intestinal polyps with mucocutaneous pigmentation of the mouth, hands, and feet. Polyps may be found anywhere from the stomach to the rectum, with most occurring in the small bowel. The polyps are classified as hamartomas of the muscularis mucosa. Patients without a family history often present with cramping abdominal pain caused by intermittent intussusception of a polyp. These patients have an increased risk of cancer with transformation of hamartomas into carcinomas. Extraintestinal (eg, ovarian, cervical, and testicular) tumors are also associated with this syndrome.

Peutz-Jeghers syndrome is diagnosed on the basis of family history, pigmented spots, and cramping abdominal pain. Recommendations for treatment consist of annual physical examinations, complete blood count (CBC), breast and pelvic examinations, testicular examinations with US, and pancreatic US. Esophagogastroduodenoscopy (EGD) and colonoscopy are recommended every 6 months. Polyps larger than 5 mm are removed during colonoscopy. Small-bowel polyps larger than 1.5 cm are surgically resected, with intraoperative endoscopy used for localization if necessary.

Familial adenomatous polyposis (FAP) is an autosomal dominant cancer predisposition syndrome characterized by more than 100 visible adenomatous polyps in the colon. It is caused by germ-line mutations in the adenomatous polyposis coli (APC) gene.

Patients present with rectal bleeding, anemia, abdominal pain, or diarrhea. Most cases are diagnosed on routine screening of children from an affected family. Increasingly, at-risk patients can be identified with molecular diagnostics (ie, screening for APC mutations). Diagnosis is established by sigmoidoscopy, which reveals a colon carpeted with polyps. Polyps occur anywhere along the GI tract, but most of the adenomatous polyps are in the colon. The risk for developing malignancy is 100%. Therefore, surgical resection of the entire colon is necessary. (See the images below.)

The transanal appearance of a child with familial

The transanal appearance of a child with familial polyposis before resection.

Surgical specimen of the colon in a patient with f

Surgical specimen of the colon in a patient with familial polyposis after total colectomy with ileoanal anastomosis. Note the carpetlike appearance of the mucosa covered with polyps.

Operative options for FAP include total abdominal colectomy with ileorectal anastomosis, which requires frequent surveillance of the rectal stump, and restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA), which has shown good long-term results in function and quality of life. [18, 19] Annual upper and lower endoscopy is recommended in all patients. Resection of remaining polyps should be performed for polyps larger than 1 cm, rapidly enlarging polyps, or polyps with severe dysplasia.

Gardner syndrome is an autosomal dominant disorder described as the association between colonic FAP and multiple osteomas, fibromas, and epidermoid cysts. The natural history and treatment of the colonic polyps mimics that for patients with FAP. Turcot syndrome is the association of colonic FAP and brain tumors.

Lymphoid polyps are pseudopolyps of submucosal intestinal lymphatic tissue secondary to hyperplasia due to nonspecific infectious causes. These polyps may ulcerate and erode the overlying mucosa, bleed, and cause chronic anemia. Colonoscopy and contrast enema, individually or in combination, are the diagnostic modalities of choice. The appearance of these polyps on either technique shows a morphologic distinction from juvenile or adenomatous polyps. No treatment is necessary, and therapy is directed toward eradicating the underlying infectious process.

Esophageal polyps in children are rare (0.14%) and are believed to be related to mucosal injury (eg, from GERD or esophagitis). [20, 21] Patients most often present with vomiting, abdominal pain, and bleeding. Diagnosis is made by means of endoscopy and biopsy. Treatment options include antacid therapy, as well as antireflux surgery or polypectomy.

eMedicine Logo

Colorectal Carcinoma

Colorectal carcinoma is the most common colonic malignancy in children and occurs with an incidence of 1.3-2 cases per million population. Predisposing factors are noted in 10-25% of childhood colorectal cancers, and the rest arise spontaneously. The two main premalignant conditions giving rise to colorectal cancers are as follows:

The risk of developing adenocarcinoma of the colon or rectum in ulcerative colitis is 3% during the first 10 years of disease, and this increases 10-15% in each subsequent decade. Patients with Crohn disease have a cancer risk 20 times higher than the general population and require regular surveillance and random biopsies.

In the sporadic type of colorectal cancers, the predominant histologic type appears to be mucinous adenocarcinoma (as shown below), occurring in up to 80% of patients. Mucinous adenocarcinoma is associated with the worst prognosis. Children present with nonspecific abdominal symptoms, including cramping abdominal pain, vomiting, and rectal bleeding. Workup includes barium enema, colonoscopy, and CT.

Surgery was performed for colonic obstruction in a

Surgery was performed for colonic obstruction in a child. A stricture is demonstrated here at the time of resection, and the pathology reveals mucinous adenocarcinoma.

Most children with mucinous adenocarcinoma present with advanced disease secondary to delay in diagnosis. In one of the larger series, because of the predominantly aggressive mucinous histology, complete resection was achieved in only 30% of children. Surgery with the intent to cure consists of a radical resection of the portion of colon involved, its mesentery, and the surrounding lymphatics. Palliative therapy includes permanent colostomy to relieve obstruction. Adjuvant chemotherapy and radiation are used, but very little survival benefit has been demonstrated. The 5-year survival rate ranges from 5% to 28%, and this directly correlates with the completeness of resection.

eMedicine Logo

  1. PDQ Pediatric Treatment Editorial Board. Rare cancers of childhood treatment (PDQ®): health professional version. National Center for Biotechnology Information. Available at https://www.ncbi.nlm.nih.gov/books/NBK65876/. October 7, 2021; Accessed: April 18, 2022.
  2. Asselin BL. Epidemiology of childhood and adolescent cancer. Kliegman RM, Stanton BMD, St Geme J, Schor NF, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia: Elsevier; 2016. Vol 2: 2416-8.
  3. Soccorso G, Parikh DH. Esophageal replacement in children: Challenges and long-term outcomes. J Indian Assoc Pediatr Surg. 2016 Jul-Sep. 21 (3):98-105. [QxMD MEDLINE Link]. [Full Text].
  4. Gillies RS, Middleton MR, Han C, Marshall RE, Maynard ND, Bradley KM, et al. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. Br J Surg. 2012 Feb. 99 (2):239-45. [QxMD MEDLINE Link].
  5. Dahms BB, Rothstein FC. Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. Gastroenterology. 1984 Feb. 86 (2):318-23. [QxMD MEDLINE Link].
  6. Singendonk MMJ, Tabbers MM, Benninga MA, Langendam MW. Pediatric Gastroesophageal Reflux Disease: Systematic Review on Prognosis and Prognostic Factors. J Pediatr Gastroenterol Nutr. 2018 Feb. 66 (2):239-243. [QxMD MEDLINE Link].
  7. Tanţău M, Laszlo M, Tanţău A. Barrett's Esophagus - State of the Art. Chirurgia (Bucur). 2018 Jan-Feb. 113 (1):46-60. [QxMD MEDLINE Link].
  8. Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology. 2018 Jan. 154 (2):267-276. [QxMD MEDLINE Link].
  9. Tullie L, Kelay A, Bethell GS, Major C, Hall NJ. Barrett's oesophagus and oesophageal cancer following oesophageal atresia repair: a systematic review. BJS Open. 2021 Jul 6. 5 (4):[QxMD MEDLINE Link]. [Full Text].
  10. Attard TM, Omar U, Glynn EF, Stoecklein N, St Peter SD, Thomson MA. Gastric cancer in the pediatric population, a multicenter cross-sectional analysis of presentation and coexisting comorbidities. J Cancer Res Clin Oncol. 2022 Apr 18. [QxMD MEDLINE Link].
  11. Bethel CA, Bhattacharyya N, Hutchinson C, Ruymann F, Cooney DR. Alimentary tract malignancies in children. J Pediatr Surg. 1997 Jul. 32 (7):1004-8; discussion 1008-9. [QxMD MEDLINE Link].
  12. Boot H. Diagnosis and staging in gastrointestinal lymphoma. Best Pract Res Clin Gastroenterol. 2010 Feb. 24 (1):3-12. [QxMD MEDLINE Link].
  13. Özcan HN, Yavuz ÖÖ, Ekinci S, Oguz B, Kutluk T, Haliloglu M. Imaging findings of gastrointestinal tract tumors in children and adolescents. Insights Imaging. 2022 Mar 22. 13 (1):51. [QxMD MEDLINE Link]. [Full Text].
  14. Fallon SC, Redell MS, El-Bietar J, Lopez ME, Vasudevan SA, Brandt ML. Intestinal perforation after treatment of Burkitt's lymphoma: case report and review of the literature. J Pediatr Surg. 2013 Feb. 48 (2):436-40. [QxMD MEDLINE Link].
  15. Ranaweera C, Brar A, Somers GR, Sheikh F, Pierro A, Zani A. Management of pediatric appendiceal carcinoid: a single institution experience from 5000 appendectomies. Pediatr Surg Int. 2019 Dec. 35 (12):1427-1430. [QxMD MEDLINE Link].
  16. Kay M, Eng K, Wyllie R. Colonic polyps and polyposis syndromes in pediatric patients. Curr Opin Pediatr. 2015 Oct. 27 (5):634-41. [QxMD MEDLINE Link].
  17. Malandra M, Kaur S, Chogle A. Utility of Routine Colonic Biopsies in Pediatric Colonoscopic Polypectomy for Benign Juvenile Hamartomatous Polyps. J Pediatr Gastroenterol Nutr. 2017 Apr. 64 (4):555-558. [QxMD MEDLINE Link].
  18. Zmora O, Natanson M, Dotan I, Vinograd I, Nagar H, Rabau M, et al. Long-term functional and quality-of-life outcomes after IPAA in children. Dis Colon Rectum. 2013 Feb. 56 (2):198-204. [QxMD MEDLINE Link].
  19. Ozdemir Y, Kiran RP, Erem HH, Aytac E, Gorgun E, Magnuson D, et al. Functional outcomes and complications after restorative proctocolectomy and ileal pouch anal anastomosis in the pediatric population. J Am Coll Surg. 2014 Mar. 218 (3):328-35. [QxMD MEDLINE Link].
  20. Septer S, Cuffari C, Attard TM. Esophageal polyps in pediatric patients undergoing routine diagnostic upper gastrointestinal endoscopy: a multicenter study. Dis Esophagus. 2014 Jan. 27 (1):24-9. [QxMD MEDLINE Link].
  21. Cakir M, Akbulut UE, Aydin-Mungan S. Esophageal polyps in children. J Pediatr Gastroenterol Nutr. 2014 Feb. 58 (2):e20-2. [QxMD MEDLINE Link].

Previous

Next

Author

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA Executive Vice President, Chief Medical and Academic Officer, Renown Heath

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American College of Healthcare Executives, American Society of Pediatric Hematology/Oncology, Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Diana Farmer, MD Professor and Chief of Pediatric Surgery, Vice Chair, Department of Surgery, University of California, San Francisco, School of Medicine; Surgeon-in-Chief, UCSF Children's Hospital

Diana Farmer, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Surgeons, American Pediatric Surgical Association

Disclosure: Nothing to disclose.

Daniel J Stephens, MD Clinical and Research Fellow in Surgical Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health (NIH)

Daniel J Stephens, MD is a member of the following medical societies: American College of Surgeons

Disclosure: Nothing to disclose.

Acknowledgements

Lisa P Abramson, MD Fellow, Department of Pediatric Surgery, Children's Memorial Hospital of Chicago

Lisa P Abramson, MD is a member of the following medical societies: Alpha Omega Alpha and American College of Surgeons

Disclosure: Nothing to disclose.

Mary Beth Madonna, MD Assistant Professor, Department of Surgery, Division of Pediatric Surgery, Northwestern University Medical School; Consulting Staff, Children's Memorial Hospital of Chicago

Disclosure: Nothing to disclose.